Stock Movers: Merck Buys Cidara Therapeutics, Stubhub Lacks Forecast, WBD Acquisition Interest

Merck Acquires Cidara Therapeutics

• 💊 Cidara Therapeutics (CDTX) shares surged over 100% following Merck's agreement to acquire the biotech company for approximately $9.2 billion.
• 📈 Merck aims to expand its treatment portfolio to offset anticipated $18 billion in sales erosion from patent expirations over the next five years, notably for its best-selling drug, Keytruda.
• 🤝 This acquisition continues a trend of competitive deals in the pharmaceutical industry, with hedge funds often drawn to biotech for potentially high asymmetrical returns.

Stubhub's IPO Quarter and Guidance Concerns

• 📉 Stubhub (STUB) shares fell significantly after the ticketing platform, in its first quarterly report since its September IPO, announced it would not provide a forecast for the current quarter.
• ⏳ CEO Eric Baker cited a long-term approach and variability in ticket sale timing as reasons for the lack of short-term guidance, with a 2026 outlook planned for the fourth-quarter results.
• ⚠️ Investors reacted negatively, with some analysts suggesting a lack of immediate earnings guidance is unexpected for new IPOs, leading to increased short interest.

Warner Bros. Discovery Acquisition Speculation

• 📰 Warner Bros. Discovery (WBD) shares rallied on reports from The Wall Street Journal that Paramount, Comcast, and Netflix are preparing bids for the media giant, with a bid cutoff set for November 20th.
• 🤝 Warner Bros. Discovery amended CEO David Zaslav's contract to ensure his stock options remain eligible to vest even if the company is sold, signaling a potential sale.
• 💰 The company, with an enterprise value around $90 billion, may command a premium, potentially reaching $100 billion, making it a transformative deal for any acquiring entity.
• 📈 The speaker believes the company should be a $40 stock, indicating significant upside potential.